News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Acumen Pharmaceuticals Inc. Co-Founders Link Alzheimer's Cause to Insulin Resistance


10/22/2007 10:07:07 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Acumen Pharmaceuticals, a leading pre-clinical biotech company in Alzheimer’s therapeutics, announced the publication of a groundbreaking study demonstrating that ADDLs (amyloid ß-derived diffusible ligands) block key insulin signaling pathways in the brain. The study, co-authored by Acumen founder and chief science officer Dr. Grant Krafft, former Acumen scientist Dr. Wei-Qin Zhao, and scientists in the laboratory of Acumen co-founder Dr. William Klein, appeared in the recent issue of the Federation of American Societies for Experimental Biology (FASEB) Journal.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES